Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Blankenfelde-Mahlow – page 63

1 867 clinical trials in Blankenfelde-Mahlow, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Blankenfelde-Mahlow at a glance
1 867
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 867 trials in Blankenfelde-Mahlow

Open in trial search

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Angina pectoris

Not yet recruiting

Study of Sublingual Glyceryl Trinitrate Spray to Reduce Angina in Adults with Symptomatic Coronary Artery Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glyceryl Trinitrate
  • Sponsor:G. Pohl-Boskamp GmbH & Co. KG

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Angelman's syndrome

Not yet recruiting

Study of the safety and efficacy of intrathecal rugonersen sodium in children and adults with Angelman syndrome

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Sponsor:Ohb Pediatrics Limited

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Betula Pendula Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Psychotic disorder+2

Not yet recruiting

A Randomized Controlled Trial of Cannabidiol vs Placebo Augmentation in Patients with First Episode Psychosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Cannabidiol
  • Sponsor:University Of Oxford

Influenza

Not yet recruiting

A Phase 3 Study of Efitazanamivir Alfa for Preventing Influenza in Adults and Adolescents at High Risk of Complications

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Cidara Therapeutics Inc.

Complicated fracture

Not yet recruiting

A study of local iloprost therapy to improve bone healing in patients with high‑risk fractures

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Iloprost Trometamol
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Blankenfelde-Mahlow

What the registry says about research in the country

01 Psoriasis Research

Comprehensive studies evaluating new therapeutic approaches for moderate to severe plaque psoriasis, including multiple clinical trials testing novel treatments and comparing their effectiveness to existing options.

  • Treatment evaluation studies
  • Long-term safety assessments
  • Comparative efficacy research

Multiple promising compounds being investigated to expand treatment options for patients with persistent symptoms.

02 Atopic Dermatitis Studies

Innovative research focusing on moderate to severe atopic dermatitis, investigating both standalone treatments and combination therapies with topical corticosteroids.

  • Novel biological therapies
  • Dose optimization studies
  • Adolescent and adult treatments

Emphasis on developing solutions for patients who haven't responded well to conventional treatments.

03 Specialized Dermatological Conditions

Research encompassing various skin conditions including chronic hand eczema, vitiligo, and hidradenitis suppurativa.

  • Targeted therapies
  • Novel treatment approaches
  • Long-term management strategies

Focus on developing effective treatments for conditions that significantly impact quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.